Document Detail

Cardioprotective properties of bradykinin: role of the B(2) receptor.
MedLine Citation:
PMID:  20505673     Owner:  NLM     Status:  In-Process    
Following the introduction of angiotensin-converting enzyme (ACE) inhibitors in the treatment of hypertension and ischemic heart disease, there has been increasing interest in the bradykinin-mediated aspects of ACE inhibition. Several preclinical and clinical studies have been conducted using genetically engineered animals or pharmacological agonists and antagonists of the two receptors of bradykinin, B(1)R and B(2)R. The results have mostly indicated that the B(1)R, whose expression is induced by tissue damage, seem to have mostly noxious effects, whereas the constitutively expressed B(2)R, when activated, exert mostly beneficial actions. Accumulating evidence in the recent literature suggests that the B(2)R have an important role in the process of ischemic post-conditioning that limits the ischemia/reperfusion injury of the myocardium. In this article, we describe a series of experiments conducted on mice submitted to acute myocardial infarct and treated either with ACE inhibition (which produces potentiation of bradykinin resulting in non-selective B(1)R and B(2)R activation) or with a potent and highly selective B(2)R agonist. These data suggest that this latter pharmacological approach offers functional and structural benefits and is therefore a promising cardioprotective therapeutic modality against acute ischemic events.
Athanasios J Manolis; Maria E Marketou; Irene Gavras; Haralambos Gavras
Related Documents :
10893233 - Delayed reversal of shape change in cells expressing fp(b) prostanoid receptors. possib...
16737803 - Investigation of the pronounced synergism between prostaglandin e2 and other constricto...
7970183 - Role of excitatory amino acid receptors in the mediation of the nociceptive response to...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-05-27
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  33     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  772-7     Citation Subset:  IM    
Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum phosphate in white-coat hypertensive patients: focus on dipping status and metabolic syndrome.
Next Document:  Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II ...